Department of Rheumatology, Changsha Hospital of Traditional Chinese Medicine, Changsha, China.
Department of Intensive Care Unit, Changsha Hospital of Traditional Chinese Medicine, Changsha, China.
Adv Rheumatol. 2023 Nov 1;63(1):54. doi: 10.1186/s42358-023-00335-x.
This study aimed to analyze the safety and efficacy of COVID-19 vaccines among patients with chronic immune-mediated inflammatory disease (IMID) in China.
Participants who were diagnosed with a chronic IMID were eligible for inclusion in this study. Age- and sex-matched healthy vaccinated individuals were set as the control group. All participants received two doses of the inactivated CoronaVac vaccine or three doses of the recombinant protein subunit vaccine ZF2001. Adverse events, IMID activity after vaccination, and the rate of COVID-19 in the two groups were compared.
There were 158 patients in the IMID group, with an average age of 40 ± 14 years old, and 98 female subjects. In the IMID group, 123 patients received the inactivated CoronaVac vaccine, and 35 patients received the recombinant protein subunit vaccine ZF2001. There were 153 individuals in the control group, including 122 who received the CoronaVac vaccine and 31 who received the recombinant protein subunit vaccine ZF2001. The frequency of vaccine-related adverse events in the IMID group was less than that in the control group, all of which were mild local effects, and no serious events occurred. Of note, no disease flares occurred in the IMID group. No participants in either group subsequently got COVID-19, so the incidence rate was 0% in both groups.
COVID-19 vaccination was found to be safe for IMID subjects, any adverse events were mild, and vaccination did not increase the risk of disease activity. Meanwhile, vaccination could effectively reduce the incidence of COVID-19 in IMID patients. In the future, studies with a larger sample size and a longer duration are needed.
本研究旨在分析中国慢性免疫介导的炎症性疾病（IMID）患者接种 COVID-19 疫苗的安全性和有效性。
本研究纳入了诊断为慢性 IMID 的参与者。年龄和性别匹配的健康接种者被设为对照组。所有参与者均接种两剂灭活的 CoronaVac 疫苗或三剂重组蛋白亚单位疫苗 ZF2001。比较两组的不良事件、接种后 IMID 活动情况以及 COVID-19 的发生率。
IMID 组有 158 例患者，平均年龄为 40±14 岁，其中女性 98 例。在 IMID 组中，123 例患者接种了灭活的 CoronaVac 疫苗，35 例患者接种了重组蛋白亚单位疫苗 ZF2001。对照组有 153 例患者，其中 122 例接种了 CoronaVac 疫苗，31 例接种了重组蛋白亚单位疫苗 ZF2001。IMID 组疫苗相关不良事件的发生频率低于对照组，均为轻度局部反应，未发生严重事件。值得注意的是，IMID 组未发生疾病发作。两组均无患者随后感染 COVID-19，因此两组的发病率均为 0%。
COVID-19 疫苗接种对 IMID 患者是安全的，任何不良事件均为轻度，且接种不会增加疾病活动的风险。同时，疫苗接种可有效降低 IMID 患者 COVID-19 的发病率。未来需要进行更大样本量和更长随访时间的研究。
